Advertisement

Mechanisms for Alternative Treatments in Parkinson’s Disease: Acupuncture, Tai Chi, and Other Treatments

  • Bijan D. Ghaffari
  • Benzi KlugerEmail author
Movement Disorders (M Okun, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Movement Disorders

Abstract

At least 40 % of patients with Parkinson’s disease (PD) use one or more forms of alternative therapy (AT) to complement standard treatments. This article reviews the commonest forms of AT for PD, including acupuncture, tai chi, yoga, mindfulness, massage, herbal medicine, and cannabis. We discuss the current evidence for the clinical efficacy of each AT and discuss potential mechanisms, including those suggested by animal and human studies. With a few notable exceptions, none of the treatments examined were investigated rigorously enough to draw definitive conclusions about efficacy or mechanism. Tai chi, acupuncture, Mucuna pruriens, cannabinoids, and music therapy have all been proposed to work through specific mechanisms, although current evidence is insufficient to support or refute these claims, with the possible exception of Mucuna pruriens (which contains levodopa). It is likely that most ATs predominantly treat PD patients through general mechanisms, including placebo effects, stress reduction, and improved mood and sleep, and AT may provide patients with a greater locus of control regarding their illness.

Keywords

Parkinson’s disease Alternative medecine Acupuncture Tai chi 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Bijan D. Ghaffari declares that he has no conflict of interest.

Benzi Kluger has received grants from the Michael J. Fox Foundation for Parkinson's Research, the National Institutes of Health, the Army Research Office, and the Veteran Affairs Medical Center. He has also received honorarium from the Parkinson Association of the Rockies, the Davis Phinney Foundation, and the Parkinson's Disease Foundation.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–6.PubMedGoogle Scholar
  2. 2.
    Bernal-Pacheco O, Limotai N, Go CL, Fernandez HH. Nonmotor manifestations in Parkinson disease. Neurologist. 2012;18(1):1–16.PubMedGoogle Scholar
  3. 3.
    Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl 4):S1–136.PubMedGoogle Scholar
  4. 4.
    Hemmerle AM, Herman JP, Seroogy KB. Stress, depression and Parkinson's disease. Exp Neurol. 2012;233(1):79–86.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2008;23(5):631–40.PubMedGoogle Scholar
  6. 6.
    Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson's disease. Neurology. 2001;57(5):790–4.PubMedGoogle Scholar
  7. 7.
    Tan LC, Lau PN, Jamora RD, Chan ES. Use of complementary therapies in patients with Parkinson's disease in Singapore. Mov Disord. 2006;21(1):86–9.PubMedGoogle Scholar
  8. 8.
    Lokk J, Nilsson M. Frequency, type and factors associated with the use of complementary and alternative medicine in patients with Parkinson's disease at a neurological outpatient clinic. Parkinsonism Relat Disord. 2010;16(8):540–4.PubMedGoogle Scholar
  9. 9.
    Angell M, Kassirer JP. Alternative medicine–the risks of untested and unregulated remedies. N Engl J Med. 1998;339(12):839–41.PubMedGoogle Scholar
  10. 10.
    Shi GX, Yang XM, Liu CZ, Wang LP. Factors contributing to therapeutic effects evaluated in acupuncture clinical trials. Trials. 2012;13:42.PubMedCentralPubMedGoogle Scholar
  11. 11.
    de la Fuente-Fernández R, Schulzer M, Stoessl JA. Placebo effect in neurological disorders. Lancet Neurol. 2002;1:85–91.PubMedGoogle Scholar
  12. 12.
    Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008;23(5):690–9.PubMedGoogle Scholar
  13. 13.
    de la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl JA. Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science. 2001;293(5532):1164–6.PubMedGoogle Scholar
  14. 14.
    Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008;23(5):700–7.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci. 2009;1156:198–210.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Schwab RS, Zieper I. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease. Psychiatr Neurol. 1965;150(6):345–57.Google Scholar
  17. 17.
    Zampieri M, de Souza EAP. Locus of control, depression, and quality of life in Parkinson's Disease. J Health Psychol. 2011;16(6):980–7.PubMedGoogle Scholar
  18. 18.
    Gruber-Baldini AL, Ye J, Anderson KE, Shulman LM. Effects of optimism/pessimism and locus of control on disability and quality of life in Parkinson's disease. Parkinsonism Relat Disord. 2009;15(9):665–9.PubMedGoogle Scholar
  19. 19.
    Lam YC, Kum WF, Durairajan SSK, Lu JH, Man SC, Xu M, et al. Efficacy and safety of acupuncture for idiopathic Parkinson's disease: a systematic review. J Altern Complement Med. 2008;14(6):663–71.PubMedGoogle Scholar
  20. 20.
    Lee MS, Shin B-C, Kong JC, Ernst E. Effectiveness of acupuncture for Parkinson's disease: a systematic review. Mov Disord. 2008;23(11):1505–15.PubMedGoogle Scholar
  21. 21.
    Lee H-S, Park H-L, Lee S-J, Shin B-C, Choi J-Y, Lee MS. Scalp acupuncture for Parkinson's disease: a systematic review of randomized controlled trials. Chin J Integr Med. 2013;19(4):297–306.PubMedGoogle Scholar
  22. 22.
    Cho S-Y, Shim S-R, Rhee HY, Park H-J, Jung W-S, Moon S-K, et al. Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2012;18(8):948–52.PubMedGoogle Scholar
  23. 23.••
    Li F, Harmer P, Fitzgerald K, Eckstrom E, Stock R, Galver J, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med. 2012;366(6):511–9. This is a large, well-designed trial of tai chi including active exercise control groups.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Li F, Harmer P, Liu Y, Eckstrom E, Fitzgerald K, Stock R, et al. A randomized controlled trial of patient-reported outcomes with tai chi exercise in Parkinson's disease. Mov Disord. 2013. doi: 10.1002/mds.25787.Google Scholar
  25. 25.
    Lee MS, Lam P, Ernst E. Effectiveness of tai chi for Parkinson's disease: a critical review. Parkinsonism Relat Disord. 2008;14(8):589–94.PubMedGoogle Scholar
  26. 26.
    Nocera JR, Amano S, Vallabhajosula S, Hass CJ. Tai Chi exercise to improve non-motor symptoms of Parkinson's disease. J Yoga Phys Ther. 2013;3:137. doi: 10.4172/2157-7595.1000137.Google Scholar
  27. 27.
    Amano S, Nocera JR, Vallabhajosula S, Juncos JL, Gregor RJ, Waddell DE, et al. The effect of Tai Chi exercise on gait initiation and gait performance in persons with Parkinson's disease. Parkinsonism Relat Disord. 2013;19(11):955–60.PubMedGoogle Scholar
  28. 28.
    Schmitz-Hübsch T, Pyfer D, Kielwein K, Fimmers R, Klockgether T, Wüllner U. Qigong exercise for the symptoms of Parkinson's disease: a randomized, controlled pilot study. Mov Disord. 2006;21(4):543–8.PubMedGoogle Scholar
  29. 29.
    Burini D, Farabollini B, Iacucci S, Rimatori C, Riccardi G, Capecci M, et al. A randomised controlled cross-over trial of aerobic training versus Qigong in advanced Parkinson's disease. Eur Medicophys. 2006;42(3):231–8.Google Scholar
  30. 30.
    Colgrove YS, Sharma N, Kluding P, Potter D, Imming K, VandeHoef J, et al. Effect of yoga on motor function in people with Parkinson’s disease: a randomized controlled pilot study. J Yoga Phys Ther. 2012;2:112. doi: 10.4172/2157-7595.1000112.Google Scholar
  31. 31.
    Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75(12):1672–7.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541–50.PubMedGoogle Scholar
  33. 33.
    Müller T, Büttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003;341(3):201–4.PubMedGoogle Scholar
  34. 34.
    Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord. 2009;24(7):979–83.PubMedGoogle Scholar
  35. 35.
    Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328(3):176–83.Google Scholar
  36. 36.
    Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63(7):1245–50.PubMedGoogle Scholar
  37. 37.
    Paterson C, Allen JA, Browning M, Barlow G, Ewings P. A pilot study of therapeutic massage for people with Parkinson's disease: the added value of user involvement. Complement Ther Clin Pract. 2005;11(3):161–71.PubMedGoogle Scholar
  38. 38.
    Hernandez-Reif MFT, Largie S, Cullan C, Beutler J, Sanders C, Weiner W, et al. Parkinson's disease symptoms are differently affected by massage therapy vs. progressive muscle relaxation: a pilot study. J Bodyw Mov Ther. 2002;6:177–82.Google Scholar
  39. 39.
    Törnhage C-J, Skogar Ö, Borg A, Larsson B, Robertsson L, Andersson L, et al. Short- and long-term effects of tactile massage on salivary cortisol concentrations in Parkinson’s disease: a randomised controlled pilot study. BMC Complement Alternat Med. 2013;13:357.Google Scholar
  40. 40.
    Craig LH, Svircev A, Haber M, Juncos JL. Controlled pilot study of the effects of neuromuscular therapy in patients with Parkinson's disease. Mov Disord. 2006;21(12):2127–33.PubMedGoogle Scholar
  41. 41.
    Stallibrass C, Sissons P, Chalmers C. Randomized controlled trial of the Alexander technique for idiopathic Parkinson's disease. Clin Rehabil. 2002;16(7):695–708.PubMedGoogle Scholar
  42. 42.
    Turbanski S, Haas CT, Schmidtbleicher D, Friedrich A, Duisberg P. Effects of random whole-body vibration on postural control in Parkinson's disease. Res Sports Med. 2005;13(3):243–56.PubMedGoogle Scholar
  43. 43.
    Haas CT, Turbanski S, Kessler K, Schmidtbleicher D. The effects of random whole-body-vibration on motor symptoms in Parkinson's disease. NeuroRehabilitation. 2006;21(1):29–36.PubMedGoogle Scholar
  44. 44.
    Kapur SS, Stebbins GT, Goetz CG. Vibration therapy for Parkinson's disease: Charcot's studies revisited. J Park Dis. 2012;2(1):23–7.Google Scholar
  45. 45.
    Ebersbach G, Edler D, Kaufhold O, Wissel J. Whole body vibration versus conventional physiotherapy to improve balance and gait in Parkinson's disease. Arch Phys Med Rehabil. 2008;89(3):399–403.PubMedGoogle Scholar
  46. 46.
    Arias P, Chouza M, Vivas J, Cudeiro J. Effect of whole body vibration in Parkinson's disease: a controlled study. Mov Disord. 2009;24(6):891–8.PubMedGoogle Scholar
  47. 47.
    Pacchetti C, Mancini F, Aglieri R, Fundarò C, Martignoni E, Nappi G. Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. Psychosom Med. 2000;62(3):386–93.PubMedGoogle Scholar
  48. 48.
    Hackney ME, Earhart GM. Effects of dance on movement control in Parkinson's disease: a comparison of Argentine tango and American ballroom. J Rehabil Med. 2009;41(6):475–81.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Duncan RP, Earhart GM. Randomized controlled trial of community-based dancing to modify disease progression in Parkinson disease. Neurorehabil Neural Repair. 2012;26(2):132–43.PubMedGoogle Scholar
  50. 50.
    Foster ER, Golden L, Duncan RP, Earhart GM. Community-based Argentine tango dance program is associated with increased activity participation among individuals with Parkinson's disease. Arch Phys Med Rehabil. 2013;94(2):240–9.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Hackney ME, Earhart GM. Health-related quality of life and alternative forms of exercise in Parkinson disease. Parkinsonism Relat Disord. 2009;15(9):644–8.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Hackney ME, Earhart GM. Effects of dance on gait and balance in Parkinson's disease: a comparison of partnered and nonpartnered dance movement. Neurorehabil Neural Repair. 2010;24(4):384–92.PubMedCentralPubMedGoogle Scholar
  53. 53.
    McKee KE, Hackney ME. The effects of adapted tango on spatial cognition and disease severity in Parkinson's disease. J Mot Behav. 2013;45(6):519–29.PubMedGoogle Scholar
  54. 54.
    Hackney ME, Kantorovich S, Levin R, Earhart GM. Effects of tango on functional mobility in Parkinson's disease: a preliminary study. J Neurol Phys Ther. 2007;31(4):173–9.PubMedGoogle Scholar
  55. 55.
    Takakura N, Takayama M, Kawase A, Yajima H. Double blinding with a new placebo needle: a validation study on participant blinding. Acupunct Med. 2011;29(3):203–7.PubMedGoogle Scholar
  56. 56.
    Park H-J, Lim S, Joo W-S, Yin C-S, Lee H-S, Lee H-J, et al. Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model. Exp Neurol. 2003;180(1):93–8.PubMedGoogle Scholar
  57. 57.
    Jeon S, Kim YJ, Kim S-T, Moon W, Chae Y, Kang M, et al. Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model. Proteomics. 2008;8(22):4822–32.PubMedGoogle Scholar
  58. 58.
    Kim SN, Doo AR, Park JY, Bae H, Chae Y, Shim I, et al. Acupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's disease. PLoS One. 2011;6(11):e27566.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Yeo S, Lim S, Choe I-H, Choi Y-G, Chung K-C, Jahng G-H, et al. Acupuncture stimulation on GB34 activates neural responses associated with Parkinson's disease. CNS Neurosci Ther. 2012;18(9):781–90.PubMedGoogle Scholar
  60. 60.
    Rui G, Guangjian Z, Yong W, Jie F, Yanchao C, Xi J, et al. High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats. Behav Brain Res. 2013;237:263–9.PubMedGoogle Scholar
  61. 61.
    Yeo S, Choi Y-G, Hong Y-M, Lim S. Neuroprotective changes of thalamic degeneration-related gene expression by acupuncture in an MPTP mouse model of parkinsonism: microarray analysis. Gene. 2013;515(2):329–38.PubMedGoogle Scholar
  62. 62.
    Wang H, Liang X, Wang X, Luo D, Jia J, Wang X. Electro-acupuncture stimulation improves spontaneous locomotor hyperactivity in MPTP intoxicated mice. PLoS One. 2013. doi: 10.1371/journal.pone.0064403.Google Scholar
  63. 63.
    Kang JM, Park HJ, Choi YG, Choe IH, Park JH, Kim YS, et al. Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model. Brain Res. 2007;1131(1):211–9.PubMedGoogle Scholar
  64. 64.
    Kim S-N, Doo A-R, Park J-Y, Choo HJ, Shim I, Park JJ, et al. Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance. Brain Res. 2014;1544:33–44.PubMedCentralPubMedGoogle Scholar
  65. 65.
    Huang Y, Jiang X, Zhuo Y, Tang A, Wik G. Complementary acupuncture treatment increases cerebral metabolism in patients with Parkinson's disease. Int J Neurosci. 2009;119(8):1190–7.PubMedGoogle Scholar
  66. 66.
    Chae Y, Lee H, Kim H, Kim C-H, Chang D-I, Kim K-M, et al. Parsing brain activity associated with acupuncture treatment in Parkinson's diseases. Mov Disord. 2009;24(12):1794–802.PubMedGoogle Scholar
  67. 67.
    Kim J-I, Yang EJ, Lee MS, Kim Y-S, Huh Y, Cho I-H, et al. Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson's disease. Int J Neurosci. 2011;121(4):209–17.PubMedGoogle Scholar
  68. 68.
    Esch T, Duckstein J, Welke J, Braun V. Mind/body techniques for physiological and psychological stress reduction: stress management via Tai Chi training - a pilot study. Med Sci Monit. 2007;1(11):CR488–97.Google Scholar
  69. 69.
    Gatts SK, Woollacott MH. Neural mechanisms underlying balance improvement with short term Tai Chi training. Aging Clin Exp Res. 2006;18(1):7–19.PubMedGoogle Scholar
  70. 70.•
    Schenkman M, Hall DA, Baron AE, Schwartz RS, Mettler P, Kohrt WM. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther. 2012;92(11):1395–410. This is a large randomized controlled trial comparing different forms of exercise in PD.PubMedCentralPubMedGoogle Scholar
  71. 71.
    Tran MD, Holly RG, Lashbrook J, Amsterdam EA. Effects of hatha yoga practice on the health-related aspects of physical fitness. Prev Cardiol. 2001;4(4):165–70.PubMedGoogle Scholar
  72. 72.
    Oken BS, Kishiyama S, Zajdel D, Bourdette D, Carlsen J, Haas M, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology. 2004;62(11):2058–64.PubMedGoogle Scholar
  73. 73.
    DiBenedetto M, Innes KE, Taylor AG, Rodeheaver PF, Boxer JA, Wright HJ, et al. Effect of a gentle Iyengar yoga program on gait in the elderly: an exploratory study. Arch Phys Med Rehabil. 2005;86(9):1830–7.PubMedGoogle Scholar
  74. 74.
    Granath J, Ingvarsson S, von Thiele U, Lundberg U. Stress management: a randomized study of cognitive behavioural therapy and yoga. Cogn Behav Ther. 2006;35(1):3–10.PubMedGoogle Scholar
  75. 75.
    West J, Otte C, Geher K, Johnson J, Mohr DC. Effects of hatha yoga and African dance on perceived stress, affect, and salivary cortisol. Ann Behav Med. 2004;28(2):114–8.PubMedGoogle Scholar
  76. 76.
    Hall E, Verheyden G, Ashburn A. Effect of a yoga programme on an individual with Parkinson's disease: a single-subject design. Disabil Rehabil. 2011;33(15–16):1483–9.PubMedGoogle Scholar
  77. 77.
    Zeiger HP. Teachng yoga to those with Parkinson’s. Yoga Ther Today. 2009;5(1):5–8.Google Scholar
  78. 78.
    Taylor M. Yoga therapeutics in neurologic physical therapy: application to a patient with Parkinson's disease. J Neurol Phys Ther. 2001;25:55–62.Google Scholar
  79. 79.••
    Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord. 2013;28(5):566–8. This is an interesting review of the long history of treatments for parkinsonism in traditional Indian medicine predating Western “discovery” of PD by hundreds of years.PubMedGoogle Scholar
  80. 80.
    Manyam BMK, Parikh V. Parkinson’s activity of Mucuna pruriens seed. Ann Neurosci. 2002;9:40–6.Google Scholar
  81. 81.
    Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res. 2004;18(9):706–12.PubMedGoogle Scholar
  82. 82.
    Yadav SK, Prakash J, Chouhan S, Singh SP. Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model. Neurochem Int. 2013;62(8):1039–47.PubMedGoogle Scholar
  83. 83.
    Kasture S, Pontis S, Pinna A, Schintu N, Spina L, Longoni R, et al. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. Neurotox Res. 2009;15(2):111–22.PubMedGoogle Scholar
  84. 84.
    Lieu CA, Venkiteswaran K, Gilmour TP, Rao AN, Petticoffer AC, Gilbert EV, et al. The antiparkinsonian and antidyskinetic mechanisms of Mucuna pruriens in the MPTP-treated nonhuman primate. Evid Based Complement Alternat Med. 2012;2012:840247.PubMedCentralPubMedGoogle Scholar
  85. 85.
    Lieu CA, Kunselman AR, Manyam BV, Venkiteswaran K, Subramanian T. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. Parkinsonism Relat Disord. 2010;16(7):458–65.PubMedCentralPubMedGoogle Scholar
  86. 86.
    Rabey JM, Vered Y, Shabtai H, Graff E, Korczyn AD. Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption. J Neurol Neurosurg Psychiatry. 1992;55(8):725–7.PubMedCentralPubMedGoogle Scholar
  87. 87.
    Samoylenko V, Rahman MM, Tekwani BL, Tripathi LM, Wang Y-H, Khan SI, et al. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson's disease. J Ethnopharmacol. 2010;127(2):357–67.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Schwarz MJ, Houghton PJ, Rose S, Jenner P, Lees AD. Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. Pharmacol Biochem Behav. 2003;75(3):627–33.PubMedGoogle Scholar
  89. 89.
    Rojas P, Ruiz-Sánchez E, Rojas C, Ogren SO. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neuroscience. 2012;223:246–57.PubMedGoogle Scholar
  90. 90.
    Rojas P, Montes P, Rojas C, Serrano-García N, Rojas-Castañeda JC. Effect of a phytopharmaceutical medicine, Ginko biloba extract 761, in an animal model of Parkinson's disease: therapeutic perspectives. Nutrition. 2012;28(11–12):1081–8.PubMedGoogle Scholar
  91. 91.
    Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010;10:14.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10):851–9.PubMedGoogle Scholar
  93. 93.
    Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997;42(2):261–4.PubMedGoogle Scholar
  94. 94.
    Weill Medical College of Cornell University. Effects of coenzyme Q10 (CoQ) in Parkinson disease (QE3). US National Library of Medicine 2008–2012. http://clinicaltrials.gov/ct2/show/NCT00740714.
  95. 95.
    Martin HL, Teismann P. Glutathione—a review on its role and significance in Parkinson's disease. FASEB J. 2009;23(10):3263–72.PubMedGoogle Scholar
  96. 96.
    Venderova K, Ruzicka E, Vorisek V, Visnovsky P. Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Mov Disord. 2004;19(9):1102–6.PubMedGoogle Scholar
  97. 97.
    Lotan I, Treves T, Roditi Y, Djaldetti R. Marijuana (cannabis) treatment for motor and non-motor symptoms in Parkinson’s disease: an open-label observational study. Mov Disord. 2014;37(2):41–4.Google Scholar
  98. 98.
    Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 2001;57(11):2108–11.PubMedGoogle Scholar
  99. 99.
    Morera-Herreras T, Miguelez C, Aristieta A, Ruiz-Ortega JÁ, Ugedo L. Endocannabinoid modulation of dopaminergic motor circuits. Front Pharmacol. 2012;3:110.PubMedCentralPubMedGoogle Scholar
  100. 100.
    Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis. 2005;19(1–2):96–107.PubMedGoogle Scholar
  101. 101.
    García C, Palomo-Garo C, García-Arencibia M, Ramos J, Pertwee R, Fernández-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease. Br J Pharmacol. 2011;163(7):1495–506.PubMedCentralPubMedGoogle Scholar
  102. 102.
    Kabat-Zinn J. Full catastrophe living: Using the wisdom of your body and mind to face stress, pain, and illness. New York: Delta; 2009.Google Scholar
  103. 103.
    Fitzpatrick L, Simpson J, Smith A. A qualitative analysis of mindfulness-based cognitive therapy (MBCT) in Parkinson's disease. Psychol Psychother. 2010;83(2):179–92.PubMedGoogle Scholar
  104. 104.
    Pickut BA, Van Hecke W, Kerckhofs E, Mariën P, Vanneste S, Cras P, et al. Mindfulness based intervention in Parkinson's disease leads to structural brain changes on MRI: a randomized controlled longitudinal trial. Clin Neurol Neurosurg. 2013;115(12):2419–25.PubMedGoogle Scholar
  105. 105.
    Advocat J, Russell G, Enticott J, Hassed C, Hester J, Vandenberg B. The effects of a mindfulness-based lifestyle programme for adults with Parkinson's disease: protocol for a mixed methods, randomised two-group control study. BMJ Open. 2013;3(10):e003326.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Johns C, Blake D, Sinclair A. Can reflexology maintain or improve the well-being of people with Parkinson's disease? Complement Ther Clin Pract. 2010;16(2):96–100.PubMedGoogle Scholar
  107. 107.
    Duval C, Lafontaine D, Hébert J, Leroux A, Panisset M, Boucher JP. The effect of Trager therapy on the level of evoked stretch responses in patients with Parkinson's disease and rigidity. J Manip Physiol Ther. 2002;25(7):455–64.Google Scholar
  108. 108.
    Hart S, Field T, Hernandez-Reif M, Nearing G, Shaw S, Schanberg S, et al. Anorexia nervosa symptoms are reduced by massage therapy. Eat Disord. 2001;9(4):289–99.PubMedGoogle Scholar
  109. 109.
    Field T, Schanberg S, Kuhn C, Fierro K, Henteleff T, Mueller C, et al. Bulimic adolescents benefit from massage therapy. Adolescence. 1998;33(131):555–63.PubMedGoogle Scholar
  110. 110.
    Alexander FM. Use of the self. 3rd ed. London: Integral; 1932.Google Scholar
  111. 111.
    Austin JH, Ausubel P. Enhanced respiratory muscular function in normal adults after lessons in proprioceptive musculoskeletal education without exercises. Chest. 1992;102(2):486–90.PubMedGoogle Scholar
  112. 112.
    de Dreu MJ, van der Wilk ASD, Poppe E, Kwakkel G, van Wegen EEH. Rehabilitation, exercise therapy and music in patients with Parkinson’s disease: a meta-analysis of the effects of music-based movement therapy on walking ability, balance and quality of life. Parkinsonism Relat Disord. 2012;18 Suppl 1:S114–9. doi: 10.1016/S1353-8020(11)70036-0.PubMedGoogle Scholar
  113. 113.
    Hackney ME, Earhart GM. Short duration, intensive tango dancing for Parkinson disease: an uncontrolled pilot study. Complement Ther Med. 2009;17(4):203–7.PubMedCentralPubMedGoogle Scholar
  114. 114.
    Blood AJ, Zatorre RJ. Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion. Proc Natl Acad Sci U S A. 2001;98(20):11818–23.PubMedCentralPubMedGoogle Scholar
  115. 115.
    Lim I, van Wegen E, de Goede C, Deutekom M, Nieuwboer A, Willems A, et al. Effects of external rhythmical cueing on gait in patients with Parkinson's disease: a systematic review. Clin Rehabil. 2005;19(7):695–713.PubMedGoogle Scholar
  116. 116.
    Nieuwboer A, Kwakkel G, Rochester L, Jones D, van Wegen E, Willems AM, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry. 2007;78(2):134–40.PubMedCentralPubMedGoogle Scholar
  117. 117.
    Okun MS, Lang A, Jankovic J. Reply: based on the available randomized trial patients should say no to glutathione for Parkinson's disease. Mov Disord. 2010;25(7):961–2. author reply 962–3.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations